Research Advances in the Application of siRNA Therapy in Gynecologic Tumors

doi:10.12280/gjfckx.20220961

Abstract

Abstract:

Gynecologic tumors are among the leading diseases in women in terms of morbidity and mortality, and patients with recurrence and drug resistance after conventional treatment have poor prognosis. Small interfering RNA (siRNA) is a promising tool for the treatment of gene-related diseases because of its high efficiency in gene silencing, ease of synthesis and wide range of targets. However, the clinical application of siRNA drugs still needs to face the problems of bare sequence instability, low in vivo delivery efficiency, and uncontrollable adverse effects. In recent years, the choice of vectors for in vivo delivery of siRNA drugs and the selection of suitable targets for their application have been the focus of research on siRNA therapeutics. This paper mainly reviews the recent research progress about the application of vector-modified siRNA drugs in gynecologic tumor therapy and the important potential application targets of siRNA in various gynecologic tumors.

Key words: Genital neoplasms, female, RNA, small interfering, Genetic therapy, Theranostic nanomedicine, Molecular targeted therapy

LUO Yan, SUN Ge-ge, HAN Li-ting, LI Xin. Research Advances in the Application of siRNA Therapy in Gynecologic Tumors[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 211-215.

References 34

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 1(1):7-33. doi: 10.3322/caac.21654. doi: 10.3322/caac.21654
[2]	Adams D, Gonzalez-Duarte A, O′Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis[J]. N Engl J Med, 2018, 379(1):11-21. doi: 10.1056/NEJMoa1716153. doi: 10.1056/NEJMoa1716153
[3]	Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391(6669):806-811. doi: 10.1038/35888. doi: 10.1038/35888
[4]	Sajid MI, Moazzam M, Kato S, et al. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside[J]. Pharmaceuticals (Basel), 2020, 13(10):294. doi: 10.3390/ph13100294. doi: 10.3390/ph13100294
[5]	Chen J, Zhao S, Tan W, et al. Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy[J]. Sci Rep, 2021, 11(1):20083. doi: 10.1038/s41598-021-99425-3. doi: 10.1038/s41598-021-99425-3 pmid: 34635698
[6]	Xu C, Liu W, Hu Y, et al. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy[J]. Theranostics, 2020, 10(7):3325-3339. doi: 10.7150/thno.41228. doi: 10.7150/thno.41228 pmid: 32194871
[7]	Singh MS, Ramishetti S, Landesman-Milo D, et al. Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer[J]. Small, 2021, 17(19):e2100287. doi: 10.1002/smll.202100287. doi: 10.1002/smll.202100287
[8]	Xia Y, Tang G, Wang C, et al. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer[J]. Drug Deliv, 2020, 27(1):15-25. doi: 10.1080/10717544.2019.1667452. doi: 10.1080/10717544.2019.1667452 pmid: 31830840
[9]	Wang C, Xia Y, Huo S, et al. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy[J]. Int J Nanomedicine, 2020, 15:9759-9770. doi: 10.2147/IJN.S270441. doi: 10.2147/IJN.S270441
[10]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[11]	Zhao S, Huang L, Basu P, et al. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries[J]. Cancer Lett, 2022, 525:22-32. doi: 10.1016/j.canlet.2021.10.036. doi: 10.1016/j.canlet.2021.10.036
[12]	Bian S, Zhao Y, Li F, et al. Knockdown of p62/sequestosome enhances ginsenoside Rh2-induced apoptosis in cervical cancer HeLa cells with no effect on autophagy[J]. Biosci Biotechnol Biochem, 2021, 85(5):1097-1103. doi: 10.1093/bbb/zbab019. doi: 10.1093/bbb/zbab019
[13]	Meiners A, Bäcker S, Hadrović I, et al. Specific inhibition of the Survivin-CRM1 interaction by peptide-modified molecular tweezers[J]. Nat Commun, 2021, 12(1):1505. doi: 10.1038/s41467-021-21753-9. doi: 10.1038/s41467-021-21753-9 pmid: 33686072
[14]	Mikulandra M, Kobescak A, Verillaud B, et al. Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2[J]. Cell Oncol(Dordr), 2019, 42(1):29-40. doi: 10.1007/s13402-018-0403-7. doi: 10.1007/s13402-018-0403-7
[15]	Zhou J, Guo X, Chen W, et al. Targeting survivin sensitizes cervical cancer cells to radiation treatment[J]. Bioengineered, 2020, 11(1):130-140. doi: 10.1080/21655979.2020.1717297. doi: 10.1080/21655979.2020.1717297 pmid: 31959045
[16]	Xi M, Tang W. Knockdown of Ezrin inhibited migration and invasion of cervical cancer cells in vitro[J]. Int J Immunopathol Pharmacol, 2020, 34: 2058738420930899. doi: 10.1177/2058738420930899. doi: 10.1177/2058738420930899
[17]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[18]	Zhang X, Wang LL, Wang B, et al. Effect of siRNA-induced Atg7 gene silencing on the sensitivity of ovarian cancer SKOV3 cells to cisplatin[J]. Am J Transl Res, 2020, 12(5):2052-2061. pmid: 32509199
[19]	Reyes-González JM, Quiñones-Díaz BI, Santana Y, et al. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer[J]. Cancers (Basel), 2020, 12(4):880. doi: 10.3390/cancers12040880. doi: 10.3390/cancers12040880
[20]	Löblein MT, Falke I, Eich HT, et al. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells[J]. Int J Mol Sci, 2021, 22(21):11502. doi: 10.3390/ijms222111502. doi: 10.3390/ijms222111502
[21]	Troschel FM, Palenta H, Borrmann K, et al. Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1[J]. J Cancer Res Clin Oncol, 2021, 147(11):3299-3312. doi: 10.1007/s00432-021-03743-y. doi: 10.1007/s00432-021-03743-y pmid: 34291358
[22]	Troschel FM, Minte A, Ismail YM, et al. Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer[J]. Int J Mol Sci, 2020, 21(6): 2169. doi: 10.3390/ijms21062169. doi: 10.3390/ijms21062169
[23]	Ghareghomi S, Ahmadian S, Zarghami N, et al. hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin[J]. Life Sci, 2021, 277:119621. doi: 10.1016/j.lfs.2021.119621. doi: 10.1016/j.lfs.2021.119621
[24]	Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer[J]. Am Fam Physician, 2016, 93(6):468-474. pmid: 26977831
[25]	Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer[J]. Nat Rev Dis Primers, 2021, 7(1):88. doi: 10.1038/s41572-021-00324-8. doi: 10.1038/s41572-021-00324-8 pmid: 34887451
[26]	Suzuki H, Boki H, Kamijo H, et al. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways[J]. J Invest Dermatol, 2020, 140(4):860-868.e3. doi: 10.1016/j.jid.2019.09.007. doi: S0022-202X(19)33298-1 pmid: 31622598
[27]	Chen HY, Zhou ZY, Luo YL, et al. Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer[J]. Cell Biol Int, 2021, 45(12):2557-2566. doi: 10.1002/cbin.11699. doi: 10.1002/cbin.11699
[28]	Luo Q, Fan J, Li L. Silencing YKL-40 gene can inhibit inflammatory factor expression and affects the effect of THP-1 cells on endometrial cancer[J]. Arch Gynecol Obstet, 2022, 305(2):467-473. doi: 10.1007/s00404-021-06194-5. doi: 10.1007/s00404-021-06194-5
[29]	Falke I, Troschel FM, Palenta H, et al. Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation[J]. Stem Cell Res Ther, 2022, 13(1):212. doi: 10.1186/s13287-022-02891-3. doi: 10.1186/s13287-022-02891-3 pmid: 35619161
[30]	Wei M, Zhang Y, Yang X, et al. Claudin-2 promotes colorectal cancer growth and metastasis by suppressing NDRG1 transcription[J]. Clin Transl Med, 2021, 11(12):e667. doi: 10.1002/ctm2.667. doi: 10.1002/ctm2.667 pmid: 34965023
[31]	Okada T, Konno T, Kohno T, et al. Possibility of Targeting Claudin-2 in Therapy for Human Endometrioid Endometrial Carcinoma[J]. Reprod Sci, 2020, 27(11):2092-2103. doi: 10.1007/s43032-020-00230-6. doi: 10.1007/s43032-020-00230-6 pmid: 32548807
[32]	Zhang Y, Xie X, Yeganeh PN, et al. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown[J]. Proc Natl Acad Sci U S A, 2021, 118(9):e2022830118. doi: 10.1073/pnas.2022830118. doi: 10.1073/pnas.2022830118
[33]	Meng Z, Lu M. RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?[J]. Front Immunol, 2017, 8:331. doi: 10.3389/fimmu.2017.00331. doi: 10.3389/fimmu.2017.00331 pmid: 28386261
[34]	Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation[J]. Nucleic Acids Res, 2005, 33(14):4527-4535. doi: 10.1093/nar/gki762. doi: 10.1093/nar/gki762 pmid: 16091630